Vico Therapeutics

Biotech · Leiden, NL

Clinical-stage genetic-medicines company for neurological diseases.

Founders

Judith van Deutekom (Netherlands · ♀) — An RNA-modulating therapeutics scientist who led ASO drug discovery at Prosensa and BioMarin in the Netherlands, she spun out Vico to push antisense oligonucleotide therapies for rare neurological diseases.
Luc Dochez (Belgium · ♂) — A biotech executive and dealmaker from Belgium, he co-founded and chaired Vico to commercialize a new platform of genetic medicines for CNS disorders.
Josh Mandel-Brehm (United States · ♂) — A US biotech entrepreneur experienced in RNA and neuroscience ventures, he helped co-found Vico to build antisense therapies for central nervous system diseases.
Gail Mandel (United States · ♀) — A neuroscientist whose academic work on Rett syndrome and neuronal gene regulation underpinned the company's scientific approach to genetic CNS diseases.

Date	Round	Amount
Jun 2024	Series B Vico Therapeutics, a Leiden genetic-medicines biotech, raised a EUR11.5M Series B second close from Seroba and Kurma Partners.	$12.4M
Jan 2024	Series B Vico Therapeutics, a Leiden genetic-medicines biotech, raised a EUR54M Series B led by Ackermans & van Haaren.	$58M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.